Baxter International Inc. (BAX) News
Follow Baxter International Inc. (BAX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 35 public stories across 13 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Baxter Raises 2026 Sales and EPS Guidance, Retires $864 Million Debt
Baxter raised its full-year reported sales growth outlook to 4%–5% from 3%–4% and lifted the lower end of adjusted diluted EPS guidance to $2.05 from $1.95, maintaining the $2.15 upper end. It also completed a $600 milli
EARNINGS | Nov 04, 2026, 12:33 PM UTC
M
Baxter Q3 Adjusted Earnings Fall as Net Sales Rise
Baxter International reported lower adjusted earnings and higher net sales in Q3.
EQUITY | Oct 29, 2026, 12:03 PM UTC
M
Baxter Reports Third-Quarter 2026 Results
EQUITY | Oct 29, 2026, 11:41 AM UTC
M
Baxter Raises 2026 Profit Forecast as Q3 Results Beat
EQUITY | Oct 29, 2026, 11:40 AM UTC
M
Baxter Sees FY Adjusted EPS of $2.05-$2.15
EARNINGS | Oct 29, 2026, 11:29 AM UTC
M
Baxter Returns to Profit in Q3 2026
Baxter returned to profitability in the third quarter of 2026, with revenue rising.
EARNINGS | Oct 29, 2026, 11:29 AM UTC
L
Baxter International reports third-quarter continuing-operations EPS
EARNINGS | Oct 29, 2026, 11:29 AM UTC
M
Baxter Raises 2026 Continuing Operations Sales Growth Outlook to 4%-5%
EARNINGS | Oct 29, 2026, 11:25 AM UTC
M
Baxter Reports Q3 Revenue of $2.98 Billion
Baxter reported Q3 revenue of $2.98 billion, versus FactSet’s $2.91 billion estimate.
EQUITY | Oct 29, 2026, 11:19 AM UTC
M
Baxter Posts Q3 Adjusted EPS of $0.58 per Share
Baxter reported Q3 adjusted EPS of $0.58 per share, versus FactSet's $0.52 estimate.
EARNINGS | Oct 29, 2026, 11:19 AM UTC
M
Baxter International Reports 3Q Sales of $2.98B
EARNINGS | Oct 29, 2026, 11:15 AM UTC
L
Baxter International Reports Third-Quarter Net Income of $294 Million
EARNINGS | Oct 29, 2026, 11:15 AM UTC
M
Baxter to host Q3 2026 results conference call on Oct. 29
EQUITY | Oct 07, 2026, 08:15 PM UTC
L
BAX: Operational progress, innovation, and debt reduction set the stage for future growth and value
Decentralization, continuous improvement, and debt reduction are driving operational and financial progress, with new leadership and product innovation supporting future growth. Business segments show mixed performance,
EQUITY | Sep 09, 2026, 06:32 PM UTC
L
BAX: Operational progress, margin expansion, and innovation drive growth amid ongoing portfolio optimization
Decentralization, continuous improvement, and debt reduction are driving operational and financial progress, with new leadership and product innovation supporting growth. Margin expansion and portfolio optimization remai
EQUITY | Sep 09, 2026, 05:55 PM UTC
H
Shares of medical device-related companies are trading lower amid possible sympathy with Boston Scientific after that company announced it w
Shares of medical device-related companies are trading lower amid possible sympathy with Boston Scientific after that company announced it was likely to miss its FY26 and Q3 adjusted EPS and net sales growth guidance fol
EARNINGS | Sep 08, 2026, 04:05 PM UTC
L
Sector underperformers include ADM, AEP, APA, BAX, BG
Hammerstone MarketTalk lists ADM, AEP, APA, BAX and BG among underperformers versus their S&P sector ETFs, with no catalyst supplied.
EQUITY | Aug 21, 2026, 07:47 PM UTC
L
Baxter appoints John Rogers as chief financial officer
Baxter appoints John Rogers as its chief financial officer, according to the company announcement.
EQUITY | Aug 19, 2026, 12:05 PM UTC
H
Baxter (BAX) prices upsized cash tender offers
Baxter announces the pricing for its upsized cash tender offers, but the feed provides no offer size, settlement terms, or exact pricing details.
MNA | Aug 18, 2026, 09:06 PM UTC
H
Baxter shares early tender results; upsizes prior cash tender offers
Baxter (BAX) reports early tender results and upsizes previously announced cash tender offers, as part of its ongoing tender offer activity.
MNA | Aug 18, 2026, 01:01 PM UTC
H
Banks Upgrade AXTI, IP, PLXS, SAIA
Banks upgrade multiple stocks
EQUITY | Jul 31, 2026, 11:38 AM UTC
H
BAX Upgraded to Neutral
BAX upgraded to Neutral from Sell
EQUITY | Jul 31, 2026, 10:41 AM UTC
H
Baxter Jumps After Q2 Beat, Boosted 2026 Guidance Reflects Turnaround Progress
Baxter International Inc. (NYSE: BAX ) stock is trading higher on Thursday after the company reported better-than-expected second-quarter financial results and raised its fiscal 2026 guidance. • Baxter International shar
EARNINGS | Jul 30, 2026, 03:34 PM UTC
H
BAX +16% after Q2 net sales above expectations ($2.96B vs $2.8B est) and management raising FY organic sales growth guide to +2-3% vs flat p
BAX +16% after Q2 net sales above expectations ($2.96B vs $2.8B est) and management raising FY organic sales growth guide to +2-3% vs flat previously. FY EPS guide $1.95-2.15 ex-items vs prior guidance $1.85-2.05. Revenu
EARNINGS | Jul 30, 2026, 01:54 PM UTC
H
BAX raises annual profit forecast
BAX raises annual profit forecast
EARNINGS | Jul 30, 2026, 01:38 PM UTC
H
Baxter rises 13% on Q2 revenue
Baxter Q2 revenue climbs
EQUITY | Jul 30, 2026, 11:42 AM UTC
L
BAX - Baxter Reports Second-Quarter 2026 Results
BAX - Baxter Reports Second-Quarter 2026 Results
EQUITY | Jul 30, 2026, 11:17 AM UTC
H
Baxter raises sales growth outlook
Baxter raises full-year sales growth outlook
EARNINGS | Jul 30, 2026, 11:16 AM UTC
H
Baxter International Raises FY2026 Adj EPS Guidance from $1.85-$2.05 to $1.95-$2.15 vs $1.91 Est; Raises FY2026 Sales Guidance from $11.244B
Baxter International (NYSE: BAX ) raises FY2026 Adj EPS guidance from $1.85-$2.05 to $1.95-$2.15 vs $1.91 analyst estimate. Raises FY2026 sales outlook from $11.244 billion-$11.356 billion to $11.581 billion-$11.694 bill
EARNINGS | Jul 30, 2026, 11:16 AM UTC
H
BAX Baxter RESULTS: Q2, Q2 ADJ EPS $0.54 vs. EST $0.37, Q2 REV $2.960B vs. EST $2.795B, Q2 Net Income $126M, Baxter Earnings Notes:, Outlook
BAX Baxter RESULTS: Q2, Q2 ADJ EPS $0.54 vs. EST $0.37, Q2 REV $2.960B vs. EST $2.795B, Q2 Net Income $126M, Baxter Earnings Notes:, Outlook FY REV growth 3-4%, Outlook FY ADJ EPS $1.95-2.15 vs. EST $1.91
EARNINGS | Jul 30, 2026, 11:15 AM UTC
L
BAX DXCM ENOV HSIC NUE OVV OZK TFII ABT AMZN ATRC BBNX BKR BSX CEG MCB NRG RXST SGHT TNDM VST PT changes @ UBS
BAX DXCM ENOV HSIC NUE OVV OZK TFII ABT AMZN ATRC BBNX BKR BSX CEG MCB NRG RXST SGHT TNDM VST PT changes @ UBS
EQUITY | Jul 28, 2026, 11:47 AM UTC
L
BAX Baxter: changes do not impact Co's previously issued Consolidated financial statements except for its segment disclosures
BAX Baxter: changes do not impact Co's previously issued Consolidated financial statements except for its segment disclosures
EQUITY | Jul 14, 2026, 08:20 PM UTC
L
BAX Baxter - shared corporate expenses to remain unallocated in segment reporting - SEC filing
BAX Baxter - shared corporate expenses to remain unallocated in segment reporting - SEC filing
REGULATION | Jul 14, 2026, 08:18 PM UTC
L
BAX Baxter - changes reportable segments to two segments effective Q2 2026 - SEC filing - Pharmaceuticals segment now reported within infusi
BAX Baxter - changes reportable segments to two segments effective Q2 2026 - SEC filing - Pharmaceuticals segment now reported within infusion Therapies & platforms division - SEC filing
REGULATION | Jul 14, 2026, 08:17 PM UTC
L
Evercore ISI Adjusts Price Target on Baxter International to $24 From $22
() -- Baxter International (BAX) has an average rating of hold and mean price target of $19.90, according to analysts polled by FactSet. ( covers equity, commodity and economic research from major banks and research firm
EQUITY | Jul 06, 2026, 01:22 PM UTC